174 related articles for article (PubMed ID: 11602522)
1. Blood thiols following amifostine and mesna infusions, a pediatric oncology group study.
Souid AK; Fahey RC; Aktas MK; Sayin OA; Karjoo S; Newton GL; Sadowitz PD; Dubowy RL; Bernstein ML
Drug Metab Dispos; 2001 Nov; 29(11):1460-6. PubMed ID: 11602522
[TBL] [Abstract][Full Text] [Related]
2. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
Souid AK; Fahey RC; Dubowy RL; Newton GL; Bernstein ML
Cancer Chemother Pharmacol; 1999; 44(6):498-504. PubMed ID: 10550571
[TBL] [Abstract][Full Text] [Related]
3. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys.
Bachy CM; Fazenbaker CA; Kifle G; McCarthy MP; Cassatt DR
Oncology; 2004; 67(3-4):187-93. PubMed ID: 15557777
[TBL] [Abstract][Full Text] [Related]
4. Kinetic analysis of the reactions of 4-hydroperoxycyclophosphamide and acrolein with glutathione, mesna, and WR-1065.
Tacka KA; Dabrowiak JC; Goodisman J; Souid AK
Drug Metab Dispos; 2002 Aug; 30(8):875-82. PubMed ID: 12124304
[TBL] [Abstract][Full Text] [Related]
5. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.
Pendyala L; Schwartz G; Smith P; Zdanowicz J; Murphy M; Hausheer F
Cancer Chemother Pharmacol; 2003 May; 51(5):376-84. PubMed ID: 12682786
[TBL] [Abstract][Full Text] [Related]
6. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
Schuchter LM; Hensley ML; Meropol NJ; Winer EP;
J Clin Oncol; 2002 Jun; 20(12):2895-903. PubMed ID: 12065567
[No Abstract] [Full Text] [Related]
7. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
Pendyala L; Creaven PJ; Schwartz G; Meropol NJ; Bolanowska-Higdon W; Zdanowicz J; Murphy M; Perez R
Clin Cancer Res; 2000 Apr; 6(4):1314-21. PubMed ID: 10778956
[TBL] [Abstract][Full Text] [Related]
8. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
Korst AE; Gall HE; Vermorken JB; van der Vijgh WJ
Cancer Chemother Pharmacol; 1996; 39(1-2):162-6. PubMed ID: 8995515
[TBL] [Abstract][Full Text] [Related]
10. Determination of the cytoprotective agent WR-2721 (Amifostine, Ethyol) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography.
Souid AK; Newton GL; Dubowy RL; Fahey RC; Bernstein ML
Cancer Chemother Pharmacol; 1998; 42(5):400-6. PubMed ID: 9771955
[TBL] [Abstract][Full Text] [Related]
11. Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.
Levi M; DeRemer SJ; Dou C; Ensminger WD; Smith DE
Biopharm Drug Dispos; 2004 Jan; 25(1):27-35. PubMed ID: 14716750
[TBL] [Abstract][Full Text] [Related]
12. Delayed radioprotection by NFkappaB-mediated induction of Sod2 (MnSOD) in SA-NH tumor cells after exposure to clinically used thiol-containing drugs.
Murley JS; Kataoka Y; Cao D; Li JJ; Oberley LW; Grdina DJ
Radiat Res; 2004 Nov; 162(5):536-46. PubMed ID: 15624308
[TBL] [Abstract][Full Text] [Related]
13. Metformin exhibits radiation countermeasures efficacy when used alone or in combination with sulfhydryl containing drugs.
Miller RC; Murley JS; Grdina DJ
Radiat Res; 2014 May; 181(5):464-70. PubMed ID: 24754562
[TBL] [Abstract][Full Text] [Related]
14. Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy.
Lauterburg BH; Nguyen T; Hartmann B; Junker E; Küpfer A; Cerny T
Cancer Chemother Pharmacol; 1994; 35(2):132-6. PubMed ID: 7987989
[TBL] [Abstract][Full Text] [Related]
15. Severe allergic reactions to thiol-based cytoprotective agents mesna and amifostine in a child with a supratentorial primitive neuroectodermal tumor.
Dorris K; Fouladi M; Davies SM; Perentesis JP; Lawrence JM; Chow LM; Assa'ad A; Uygungil B; Jodele S
J Pediatr Hematol Oncol; 2011 Aug; 33(6):e250-2. PubMed ID: 21646919
[TBL] [Abstract][Full Text] [Related]
16. Measurement of both protein-bound and total S-2-(3-aminopropylamino)ethanethiol (WR-1065) in blood by high-performance liquid chromatography.
Bonner HS; Shaw LM
J Chromatogr B Biomed Sci Appl; 2000 Mar; 739(2):357-62. PubMed ID: 10755379
[TBL] [Abstract][Full Text] [Related]
17. High-performance liquid chromatographic assay using electrochemical detection for the combined measurement of amifostine, WR 1065 and the disulfides in plasma.
Korst AE; Vermorken JB; van der Vijgh WJ
J Chromatogr B Biomed Sci Appl; 1997 May; 693(1):167-74. PubMed ID: 9200531
[TBL] [Abstract][Full Text] [Related]
18. Manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by the free thiol form of amifostine and tumor necrosis factor alpha.
Murley JS; Kataoka Y; Baker KL; Diamond AM; Morgan WF; Grdina DJ
Radiat Res; 2007 Apr; 167(4):465-74. PubMed ID: 17388698
[TBL] [Abstract][Full Text] [Related]
19. Binding of radioprotective thiols and disulfides in Chinese hamster V79 cell nuclei.
Newton GL; Aguilera JA; Ward JF; Fahey RC
Radiat Res; 1996 Sep; 146(3):298-305. PubMed ID: 8752308
[TBL] [Abstract][Full Text] [Related]
20. Two schedules of application for mesna and their influence on the thiol-metabolism.
Kempgens B; Kisro J; Gruber Y; Bahrs H; Wagner T
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):608-9. PubMed ID: 14692714
[No Abstract] [Full Text] [Related]
[Next] [New Search]
